ASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical group Amicus Therapeutics agreed to $940 million in payments for future sales of its kidney disease drug.
Shares in Melbourne-based Dimerix were trading 50 per cent higher on news of the breakthrough on Thursday afternoon, valuing the company at $400 million. The biotech group counts former Fortescue Metals and WorleyParsons executive Peter Meurs as its biggest shareholder, with a 13.5 per cent stake.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.